Treating lung cancer in patients with interstitial lung disease: what do we know?

[摘要] Management of interstitial lung disease (ILD) remains a challenge for patients and healthcare providers. While pirfenidone and nintedanib, so termed anti-fibrotic agents, have been shown to slow decline in pulmonary function, decrease all-cause mortality and the rate of acute exacerbations (AE-ILD) in idiopathic pulmonary fibrosis (IPF) (1-4), morbidity and mortality remain high for IPF, the most deadly ILD (5,6). In addition to progressive decline in lung function and AE-ILD, patients with IPF are at risk for pulmonary hypertension, venous thromboembolism, and lung cancer (6-8). Patients with coexistent ILD and lung cancer have a worse survival than patients with lung cancer alone (9).

[学科分类] 呼吸医学

[关键词] Lung cancer;cryoablation;interstitial lung disease;pulmonary fibrosis